Drug intelligence / Profile preview

QS-21

Development stage
Phase 3
Lead developer
Agenus
Modality
Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intramuscular, Subcutaneous
01

Overview

QS-21 is a purified natural saponin fraction derived from the bark of the soapbark tree (Quillaja saponaria Molina), native to South America. It functions as a potent immunological adjuvant and is used in vaccines and immunotherapies to enhance both humoral and cell-mediated immune responses to co-administered antigens. Mechanistically, it forms complexes with cholesterol that intercalate into cell membrane lipids of antigen-presenting cells; this creates pores in the membrane that accelerate antigen uptake and presentation. This results in increased vaccine-specific antibody production and cytotoxic T-cell responses. QS-21 has been evaluated as an adjuvant in clinical trials for vaccines targeting infectious diseases (such as COVID-19, malaria, RSV) and cancer immunotherapies[1][2][3][4][5]. It is not itself an approved pharmaceutical but has been included in several globally approved vaccines.

Brand names
Stimulon
Other names
Quillaja saponin (QS-21)Saponin QA 21V1QA-21V1QA21V1QA 21V1QS-21-apiose isomerQS21-apiose isomerQS 21-apiose isomer
02

Targets

LRs (Cholesterol-rich membrane domains)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on QS-21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on QS-21.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call